SMC recommends Opdivo® (nivolumab) for use post-surgery in specific urothelial cancer patients
February 20, 2023Business Services
(Uxbridge, Middlesex, 13 February 2023) – The Scottish Medicines Consortium (SMC) has accepted Bristol Myers Squibb’s (BMS’) nivolumab for the …
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma
February 20, 2023Business Services
PARIS, FRANCE, STRICTLY EMBARGOED until 11.00pm CET, 13 February 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced three-year minimum, …
Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic CastrationResistant Prostate Cance
February 20, 2023Business Services
BEERSE, BELGIUM, 16 February 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the …
FDA approves Apellis’ geographic atrophy treatment
February 20, 2023Medical Communications
Apellis’ Syfovre (pegcetacoplan injection) is indicated for patients with geographic atrophy (GA) with or without subfoveal involvement, and has received …
Medtronic’s extravascular defibrillator receives CE mark
February 20, 2023Medical Communications
Medtronic has received CE mark for its extravascular defibrillator. The Aurora EV-ICD™ MRI SureScan™ and Epsila EV™ MRI SureScan™ defibrillation …
Pfizer’s Lyme disease vaccine study cut due to protocol violations
February 20, 2023Medical Communications
Valneva and Pfizer have seen their Lyme disease vaccine study cut down after some clinical trial sites were revealed to …
Stryker’s Q Guidance System received FDA clearance for cranial applications
February 20, 2023Sales and Marketing
Stryker, a medical technology company, has announced that its Q Guidance System with Cranial Guidance Software received 510(k) clearance from …
Sun Pharma recalls at least 34,000 bottles of generic drug
February 13, 2023Medical Communications
Mumbai-based pharma company, Sun Pharma, has announced that it is recalling over 34,000 bottles of a generic drug, Diltiazem Hydrochloride, …
REGENXBIO presents interim phase 2 data from drug developed on NAVXpress™ platform
February 13, 2023Manufacturing and Production
REGENXBIO, a clinical-stage biotech company, has announced positive phase 2 data for their drug RXG-314, which was developed by the …
Scancell shares “highly encouraging” results from phase 1 COVID-19 vaccine trial
February 13, 2023Research and Development
Scancell Holdings PLC has shared “highly encouraging” results from its phase 1 clinical trial of its COVID-19 vaccines, says chief …
Sorrento Therapeutics’ subsidiary Scilex Holding Company acquires rights to acute migraine treatment
February 13, 2023Sales and Marketing
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, has announced that it has acquired the rights to ELYXYBTM (celecoxib oral …
UK pharma packaging giant Origin celebrates its 60th anniversary
February 13, 2023Business Services
13th FEBRUARY 2023, HULL, UK: Leading UK pharmaceutical packaging and solutions provider, Origin, is celebrating its 60th anniversary. Origin …
CYDAR MEDICAL RAISES $11.5M (£9.3M) IN SERIES A FUNDING ROUND
February 13, 2023Business Services
CAMBRIDGE, UNITED KINGDOM, 13 FEBRUARY 2023 – Cydar Medical (“Cydar” or “the Company”) a global, cloud-based surgical software company, announces …
AstraZeneca moves manufacturing to Ireland due to Britain’s tax regime
February 10, 2023Medical Communications
Big pharma giant, AstraZeneca, has announced that its plans to open a new facility in northwest England have now changed, …
SynaptixBio secures FDA Rare Paediatric Disease designation to develop treatments for TUBB4a leukodystrophy
February 10, 2023Research and Development
SynaptixBio, a UK-based biotech firm, has been granted FDA Rare Paediatric Disease (RPD) designation – an accolade which encourages the …
AbbVie expects 37% decline in Humira sales following new biosimilars hitting the US market
February 10, 2023Sales and Marketing
AbbVie Inc has announced that it expects to see a 37% decline in sales of its flagship rheumatoid arthritis drug …
FDA grants full approval to GSK for mismatch repair-deficient endometrial cancer treatment
February 10, 2023Medical Communications
GSK announced that its treatment for recurrent or advanced mismatch repair-deficient (dMMR) endometrial cancer has been granted full approval by …
RQ Bio Strengthens Board with Industry-leading Infectious Disease Experts Joining as Non-Executive Directors
February 9, 2023Business Services
LONDON, UK, 9 February 2023 — RQ Bio is scaling up at speed, with the appointment of Non-Executive Directors, Dr …
Stand Up To Cancer announces four teams dedicated to increasing diversity in clinical trials
February 9, 2023Medical Communications
Stand Up To Cancer (SU2C) has announced four teams that will focus on increasing diversity in early phase cancer clinical …
FDA grants RMAT designation for Mesoblast’s chronic low back pain treatment
February 9, 2023Medical Communications
Mesoblast Ltd, an Australian regenerative medicine company leading in allogeneic cellular medicines for inflammatory diseases, announced that its treatment for …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
